AIxCrypto Holdings (AIXC) AI Stock Analysis

• Market Cap: $12.59M
• Dividend Yield: N/A
• Average Volume (3M): 2.38M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.87
• Revenue Growth: N/A
• EPS Growth: 84.34%
• Country: US
• Employees: 4
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Pharmaceuticals
• EPS (TTM): N/A
• Shares Outstanding: 5,160,383
• 10 Day Avg. Volume: 295,576
• 30 Day Avg. Volume: 2,383,814
• PEG Ratio: <0.01
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.24
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -35.5
• Revenue Forecast (FY): N/A

No summary available

AIxCrypto Holdings Business Overview & Revenue Model

Company Description

Qualigen Therapeutics, Inc. (QLGN) is a biotechnology company that focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. The company operates in the healthcare sector, emphasizing innovative drug candidates and diagnostic technologies. Qualigen's core offerings include a pipeline of proprietary drug candidates aimed at addressing unmet medical needs in oncology and infectious diseases.

How the Company Makes Money

Qualigen Therapeutics generates revenue through multiple streams, primarily focusing on the development and commercialization of its therapeutic products. The company earns money by advancing its drug candidates through clinical trials and securing partnerships or licensing agreements with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of clinical and regulatory goals, and royalties on product sales. Additionally, Qualigen may derive revenue from its diagnostic technologies, which are used in clinical settings and research institutions. The company's financial performance is significantly influenced by its ability to successfully bring its drug candidates to market and establish strategic partnerships within the pharmaceutical industry.

AIxCrypto Holdings Financial Statement Overview

Summary

Qualigen Therapeutics faces significant financial challenges. The income statement reveals persistent revenue declines and substantial losses, while the balance sheet highlights financial instability with negative equity. Cash flow analysis indicates ongoing operational cash burn and reliance on financing. The company needs strategic financial management and operational improvements to stabilize its financial health.

Income Statement

Qualigen Therapeutics has experienced declining revenue recently, with the latest TTM period showing zero revenue. The company consistently reports significant net losses, evidenced by a negative net profit margin across recent periods. Gross profit margins are also negative, indicating cost management challenges. Historical revenue growth has been inconsistent, with recent declines. EBIT and EBITDA margins remain negative, highlighting operational inefficiencies and profitability issues.

Balance Sheet

The balance sheet shows significant financial distress, with negative stockholders' equity in the latest TTM period, indicating liabilities exceed assets. The company's debt-to-equity ratio is not meaningful due to negative equity, but high liabilities relative to assets suggest financial instability. Return on equity is negative, reflecting ongoing losses, and the equity ratio is concerning due to negative equity.

Cash Flow

Cash flow analysis shows negative operating cash flows, highlighting operational challenges. Free cash flow has been negative, indicating cash burn that may threaten sustainability without external financing. The company has relied on financing activities, as shown by cash inflows from financing, to support operations. Overall, cash flow metrics reflect a need for improved cash management and operational performance.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	5.65M	4.31M
Gross Profit	-105.58K	0.00	0.00	680.80K	1.32M	-2.88M
EBITDA	-6.48M	-5.24M	-10.95M	-13.84M	-22.32M	-11.16M
Net Income	-7.23M	-6.26M	-13.42M	-18.64M	-17.90M	-20.42M
Balance Sheet
Total Assets	43.47M	4.69M	2.03M	19.08M	22.84M	29.13M
Cash, Cash Equivalents and Short-Term Investments	38.78M	1.17M	401.80K	3.17M	17.54M	23.98M
Total Debt	3.24M	0.00	1.30M	1.76M	1.68M	630.30K
Total Liabilities	4.92M	2.01M	4.14M	10.32M	6.27M	10.83M
Stockholders Equity	38.55M	2.68M	-2.10M	7.24M	16.56M	18.29M
Cash Flow
Free Cash Flow	-7.10M	-6.33M	-10.30M	-13.57M	-14.87M	-9.97M
Operating Cash Flow	-7.10M	-6.33M	-10.30M	-13.25M	-14.73M	-9.76M
Investing Cash Flow	-2.82M	-1.91M	4.22M	-183.76K	-141.36K	-160.56K
Financing Cash Flow	48.30M	9.01M	-550.00K	2.91M	8.43M	33.76M

AIxCrypto Holdings Technical Analysis

• Last Price: 2.53

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIXC, the sentiment is undefined. The current price of 2.53 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for AIXC.

AIxCrypto Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%

AIxCrypto Holdings Corporate Events

Qualigen Therapeutics Invests in NanoSynex’s Growth

On January 28, 2025, Qualigen Therapeutics announced its participation as the first investor in the 2025 bridge funding round for NanoSynex, which aims to raise up to $500,000. This investment supports the development of NanoSynex’s Antimicrobial Susceptibility Testing technology, which is expected to significantly enhance diagnostic speed and accuracy, potentially expanding the market to $4.7 billion by 2027. NanoSynex plans to enter the EU and US markets by 2027 and 2028, respectively, with a promising pipeline and four patents protecting its technology.

Qualigen Therapeutics Appoints Graydon Bensler to Board

Graydon Bensler has been appointed as an independent board member, bringing over seven years of financial consulting and management experience. A Chartered Financial Analyst, Bensler co-founded an Ed Tech company and held key roles in investor relations and investment banking. His expertise in capital markets and public company compliance is expected to benefit the board significantly.